Trials / Completed
CompletedNCT03536884
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
A Multicenter, Randomized, Double-Blind, Secukinumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 743 (actual)
- Sponsor
- UCB Biopharma SRL · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a study to compare the efficacy of bimekizumab versus secukinumab in subjects with moderate to severe chronic plaque psoriasis (PSO).
Detailed description
The study consists of a 48-week double-blind Treatment Period, an optional 96-week open-label extension (OLE) Period and an optional 48-week OLE2 Period for eligible subjects in the USA and Canada.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bimekizumab | Subjects will receive bimekizumab at pre-specified time-points. |
| DRUG | Secukinumab | Subjects will receive secukinumab at pre-specified time-points. |
| OTHER | Placebo | Subjects will receive placebo at pre-specified time-points to maintain the blinding in the double-blind Treatment Period. |
Timeline
- Start date
- 2018-06-13
- Primary completion
- 2019-09-12
- Completion
- 2023-08-09
- First posted
- 2018-05-25
- Last updated
- 2026-04-15
- Results posted
- 2022-10-10
Locations
77 sites across 11 countries: United States, Australia, Belgium, Canada, France, Germany, Netherlands, Poland, Spain, Turkey (Türkiye), United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03536884. Inclusion in this directory is not an endorsement.